Skip to main content

Advertisement

SpringerLink
Log in

Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M (2008) Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 88:121–132

    Article  PubMed  Google Scholar 

  2. Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289:1130–1135. doi:10.1001/jama.289.9.1130

    Article  CAS  PubMed  Google Scholar 

  3. Risitano AM, Selleri C, Serio B, Marando L, Camera A, Catalano L, Scalia G, Del Vecchio L, Rotoli B (2007) Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: a pilot study. Blood 110:1692a

    Google Scholar 

  4. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A (2007) Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109:3219–3224. doi:10.1182/blood-2006-09-045625

    Article  CAS  PubMed  Google Scholar 

  5. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 3:105–110. doi:10.3816/CLM.2002.n.016

    Article  CAS  PubMed  Google Scholar 

  6. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G (2004) Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 89:1248–1252

    CAS  PubMed  Google Scholar 

  7. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357–4363. doi:10.1182/blood.V99.12.4357

    Article  CAS  PubMed  Google Scholar 

  8. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178

    CAS  PubMed  Google Scholar 

  9. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S (2006) Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:851–856. doi:10.1038/sj.bmt.1705341

    Article  CAS  PubMed  Google Scholar 

  10. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111:1816–1819. doi:10.1182/blood-2007-03-080010

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Via Pansini 5, 80131, Naples, Italy

    Antonio M. Risitano, Bianca Serio, Carmine Selleri & Bruno Rotoli

Authors
  1. Antonio M. Risitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bianca Serio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carmine Selleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Rotoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio M. Risitano.

Additional information

Contribution of the authors

AMR, CS, and BR designed the study; AMR and BS performed the study; AMR analyzed the data and wrote the paper in collaboration with BR. All authors discussed and interpreted the data and revised the paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Risitano, A.M., Serio, B., Selleri, C. et al. Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Ann Hematol 88, 1261–1262 (2009). https://doi.org/10.1007/s00277-009-0749-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0749-z

Keywords

Search

Navigation